Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects with Advanced Solid Malignancies including Lymphoma

    Cancer Categories
    • Hematologic (Blood Cancers),Lung,Skin
    Karmanos Trial ID
    • 2020-096
    NCT ID
    • NCT04137900
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator


    Primary Objectives:
    1. Dose-escalation phase (Part A): To assess the safety and tolerability of multiple doses of TAB004 and define the maximum tolerated dose (MTD) or the maximum feasible dose(MFD) (highest protocol-defined dose of TAB004 in the absence of exceeding the MTD) in subjects with advanced solid malignancies including lymphoma.
    2. Cohort-expansion phase (Part B): To further characterize the safety profile of TAB004 in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose (RP2D).
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266